

Prescribing Clinical Network

Policy Statement	Vesomni® (tamsulosin & solifenacin) for the treatment of lower urinary tract symptoms in men
Policy No:	PCN 296- 2017
Date of Issue	December - 2017
Review Date:	December - 2020 <i>(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)</i>
<p>Recommendations: The PCN does not recommend the use of the combination product Vesomni® (tamsulosin & solifenacin) as a treatment option for lower urinary tract symptoms in men and has assigned a BLACK traffic light status to this treatment</p> <p>Patients whose treatment was initiated by the NHS before this recommendation was made, must be reviewed by their NHS consultant but should be able to continue treatment until, the patient and their NHS consultant consider it appropriate to stop.</p>	
<p>Key Considerations:</p> <ul style="list-style-type: none"> • More cost effective to prescribe separate products in line with NICE guidance. • CG97: Lower urinary tract symptoms in men -: management https://www.nice.org.uk/guidance/cg97/resources/lower-urinary-tract-symptoms-in-men-management-pdf-975754394053 	
Date taken to Prescribing Clinical Network	6 th December 2017
Agreed by PCN members	18th December 2017

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG